Suppr超能文献

HLA-B*27:05和-B*27:02介导的HIV-1感染控制中CD8 T细胞反应的差异免疫优势层次结构

Differential Immunodominance Hierarchy of CD8 T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

作者信息

Adland Emily, Hill Matilda, Lavandier Nora, Csala Anna, Edwards Anne, Chen Fabian, Radkowski Marek, Kowalska Justyna D, Paraskevis Dimitrios, Hatzakis Angelos, Valenzuela-Ponce Humberto, Pfafferott Katja, Williams Ian, Pellegrino Pierre, Borrow Persephone, Mori Masahiko, Rockstroh Jürgen, Prado Julia G, Mothe Beatriz, Dalmau Judith, Martinez-Picado Javier, Tudor-Williams Gareth, Frater John, Stryhn Anette, Buus Soren, Teran Gustavo Reyes, Mallal Simon, John Mina, Buchbinder Susan, Kirk Gregory, Martin Jeffrey, Michael Nelson, Fellay Jacques, Deeks Steve, Walker Bruce, Avila-Rios Santiago, Cole David, Brander Christian, Carrington Mary, Goulder Philip

机构信息

Department of Paediatrics, University of Oxford, United Kingdom.

Department of GU Medicine, The Churchill Hospital, Oxford University NHS Foundation Trust, Oxford, United Kingdom.

出版信息

J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

Abstract

The well-characterized association between HLA-B27:05 and protection against HIV disease progression has been linked to immunodominant HLA-B27:05-restricted CD8 T-cell responses toward the conserved Gag KK10 (residues 263 to 272) and polymerase (Pol) KY9 (residues 901 to 909) epitopes. We studied the impact of the 3 amino acid differences between HLA-B27:05 and the closely related HLA-B27:02 on the HIV-specific CD8 T-cell response hierarchy and on immune control of HIV. Genetic epidemiological data indicate that both HLA-B27:02 and HLA-B27:05 are associated with slower disease progression and lower viral loads. The effect of HLA-B27:02 appeared to be consistently stronger than that of HLA-B27:05. In contrast to HLA-B27:05, the immunodominant HIV-specific HLA-B27:02-restricted CD8 T-cell response is to a Nef epitope (residues 142 to 150 [VW9]), with Pol KY9 subdominant and Gag KK10 further subdominant. This selection was driven by structural differences in the F pocket, mediated by a polymorphism between these two HLA alleles at position 81. Analysis of autologous virus sequences showed that in HLA-B27:02-positive subjects, all three of these CD8 T-cell responses impose selection pressure on the virus, whereas in HLA-B27:05-positive subjects, there is no Nef VW9-mediated selection pressure. These studies demonstrate that HLA-B27:02 mediates protection against HIV disease progression that is at least as strong as or stronger than that mediated by HLA-B27:05. In combination with the protective Gag KK10 and Pol KY9 CD8 T-cell responses that dominate HIV-specific CD8 T-cell activity in HLA-B27:05-positive subjects, a Nef VW9-specific response is additionally present and immunodominant in HLA-B27:02-positive subjects, mediated through a polymorphism at residue 81 in the F pocket, that contributes to selection pressure against HIV. CD8 T cells play a central role in successful control of HIV infection and have the potential also to mediate the eradication of viral reservoirs of infection. The principal means by which protective HLA class I molecules, such as HLA-B27:05 and HLA-B57:01, slow HIV disease progression is believed to be via the particular HIV-specific CD8 T cell responses restricted by those alleles. We focus here on HLA-B27:05, one of the best-characterized protective HLA molecules, and the closely related HLA-B27:02, which differs by only 3 amino acids and which has not been well studied in relation to control of HIV infection. We show that HLA-B27:02 is also protective against HIV disease progression, but the CD8 T-cell immunodominance hierarchy of HLA-B27:02 differs strikingly from that of HLA-B27:05. These findings indicate that the immunodominant HLA-B27:02-restricted Nef response adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV CD8 T-cell activity in HLA-B*27:05-positive subjects.

摘要

HLA - B27:05与预防HIV疾病进展之间已得到充分表征的关联,与免疫显性的HLA - B27:05限制性CD8 T细胞对保守的Gag KK10(第263至272位氨基酸)和聚合酶(Pol)KY9(第901至909位氨基酸)表位的反应有关。我们研究了HLA - B27:05与密切相关的HLA - B27:02之间3个氨基酸差异对HIV特异性CD8 T细胞反应层级以及HIV免疫控制的影响。遗传流行病学数据表明,HLA - B27:02和HLA - B27:05均与疾病进展较慢和病毒载量较低相关。HLA - B27:02的作用似乎始终比HLA - B27:05更强。与HLA - B27:05不同,免疫显性的HIV特异性HLA - B27:02限制性CD8 T细胞反应针对的是Nef表位(第142至150位氨基酸[VW9]),Pol KY9为次显性,Gag KK10更次显性。这种选择是由F口袋中的结构差异驱动的,这是由这两个HLA等位基因在第81位的多态性介导的。对自体病毒序列的分析表明,在HLA - B27:02阳性受试者中,所有这三种CD8 T细胞反应都会对病毒施加选择压力,而在HLA - B27:05阳性受试者中,则不存在Nef VW9介导的选择压力。这些研究表明,HLA - B27:02介导的预防HIV疾病进展的作用至少与HLA - B27:05介导的作用一样强或更强。在HLA - B27:05阳性受试者中主导HIV特异性CD8 T细胞活性的保护性Gag KK10和Pol KY9 CD8 T细胞反应之外,HLA - B27:02阳性受试者中还存在并占主导地位的Nef VW9特异性反应,该反应通过F口袋中第81位氨基酸的多态性介导,有助于对HIV施加选择压力。CD8 T细胞在成功控制HIV感染中起核心作用,并且也有潜力介导消除感染性病毒库。人们认为,诸如HLA - B27:05和HLA - B57:01等保护性HLA I类分子减缓HIV疾病进展的主要方式是通过受这些等位基因限制的特定HIV特异性CD8 T细胞反应。我们在此重点关注HLA - B27:05,这是特征最明确的保护性HLA分子之一,以及密切相关的HLA - B27:02,它仅相差3个氨基酸,并且在HIV感染控制方面尚未得到充分研究。我们表明,HLA - B27:02也能预防HIV疾病进展,但HLA - B27:02的CD8 T细胞免疫显性层级与HLA - B27:05的显著不同。这些发现表明,免疫显性的HLA - B27:02限制性Nef反应增加了由Gag和Pol特异性介导的保护作用,而Gag和Pol特异性在HLA - B*27:05阳性受试者的抗HIV CD8 T细胞活性中占主导地位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2cb/5790925/bf07257fe9a7/zjv0041832790001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验